explore -WSS

explore

author：entertainment 2025-09-30 15:16:31 - browse：9

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Why are Kaiser Permanente staff considering a strike?

focus

WSS

EpiPen alternative approval delay highlights citizen petition issue

Senators: Long

Senate HELP committee spars over health care workforce policies

Readout LOUD podcast: possible new ALS drug, artificial wombs

Experts study whether long Covid risk adds up with each reinfection

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

entertainment

explore

focus

Continuity nursing helped my family in our darkest PICU moments

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Novavax promises a turnaround & Lilly roils the obesity market

STAT Virtual Event: Putting AI to the Test

Hollywood unions extend contract negotiations for actors

What Congress can do to address the rural doctor shortage

Sports medicine is finally prioritizing gender equality

FDA poised to publish guidelines for clinical trial diversity

Anesthesiologist group: stop taking Ozempic before surgery

Ukraine and a new approach to mental health in war

hotspot

How Vertex's cystic fibrosis drug is changing patients' lives

CDC advisers recommend seasonal use of Pfizer RSV shot

Experts study whether long Covid risk adds up with each reinfection

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

EpiPen alternative approval delay highlights citizen petition issue

Scrutiny of post

entertainment

hotspot

focus

entertainment